About This Fund
ORI Fund II, the second fund raised by ORI Capital, has received total commitments of $260 million, reflecting strong interest from institutional, strategic, and high net worth investors globally. The fund, which closed above its original target, will invest in innovative early-stage biotech companies globally, with a focus on diagnostics, drug delivery, and therapeutics targeting areas of significant unmet medical need such as cancer, metabolic disorders, and neurodegenerative diseases.
Simone Song, the founding partner of ORI Capital, emphasized the firm’s focus on growth-oriented venture investments in the biotech sector, specifically targeting early to early to mid-stage life sciences companies developing novel therapeutics, as well as life sciences tools and diagnostics companies. The firm’s investment team, with decades of experience in the biotech and healthcare sector, will leverage the resources of the proprietary big data and AI-driven ORIZON platform to source differentiated investments and partner with companies to enhance value creation.
ORI Capital has identified several themes of fundamental innovation and structural shifts that will drive significant growth in the coming decades, including next generation small molecules, programmable nuclear acid therapies, immuno-oncology, cell therapy, and synthetic biology. The firm aims to actively deploy capital in these new approaches to support innovative companies that can bring hope to patients in need globally.